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or  decades,  immunologists  occupied  themselves  with 
trying to understand  the  initiation  of an immune  re- 
sponse. This led to a highly detailed molecular portrait of 
antigen  recognition and  activation.  Partly spurred by the 
enigma ofautoimmune conditions, recent attention has now 
focused on how immune responses are turned off. Central 
to this issue is the maintenance of  immune cell homeostasis. 
Because immune responses are potentially dangerous alter- 
ations in normal physiology, they must be carefully con- 
trolled or extinguished if the antigenic stimulus either be- 
comes too great or is successfully eliminated. One important 
mechanism  of lymphocyte control is  programmed death, 
which may occur in all immune responses. T  cells have at 
least two apoptotic pathways:  first,  active death, which is 
antigen driven, and second, passive death, which occurs  at 
the conclusion of an immune response and may be due to 
lymphokine withdrawal or other mechanisms (reviewed in 
1-3) (Fig.  1). These forms of death are molecularly distinct, 
since Fas and TNF are major participants in active but not 
passive death, and Bcl-2 or Bcl-x can abrogate passive but 
not antigen-driven death (2--4). Therefore, the cellular re- 
sponse to antigen can be viewed as a cycle of birth, propa- 
gation, and death. Memory may comprise lymphocytes that 
escape this circuit and persist (1, 5). 
The article by Simon et al.  (6) illustrates  the dangers of 
defective homeostasis by showing that somatic alterations 
in the regulation of the death-inducing molecule Fas may 
be associated with hypereosinophilia and its attendant patho- 
logical complications. Fas (also called Apo-1, CD95, and Apt) 
is  a  member of the  TNF  receptor  (TNFR)  superfamily, 
whose eldest siblings,  TNFR type I (p55) and TNFR type 
II (p75), have long been known to induce programmed cell 
death  (reviewed in 2,  7).  The other transmembrane pro- 
teins belonging to the TNFR superfamily include the low 
affanity nerve growth factor receptor (NGFR), CD27, CD30, 
CD40,  OX40, and 4-1BB. Many of these molecules have 
well-defined roles in immune regulation and homeostasis. 
These proteins  share  up  to  20-25%  amino  acid  identity, 
predominantly in cysteine-rich domains (CRDs) within the 
extracellular domain. CRDs define membership in the fam- 
ily and are necessary for ligand binding. The intracytoplas- 
mic portions of the TNFR-related proteins are unique ex- 
cept for Fas p55 TNFR and the NGFR.  These receptors 
share homology within a 70-aa "death domain" that is re- 
quired for transducing death signals  (8). The death domain 
acts as a docking site for a family of  soluble cytoplasmic sig- 
naling  proteins  that  also  contain  death  domains  (9).  The 
death domain is conserved far back in evolution, since it is 
present in a Drosophila protein, Reaper, which genetic ev- 
idence has  implicated in cell death (10).  The intracellular 
domains of other TNF family receptors are known to in- 
teract with cytosolic proteins that fall into a distinct family 
of homolognes called TRAF (for TNFR-associated factor) 
(11,  12). 
The ligands for the TNFR-like receptors also constitute 
a gene superfamily and share structural similarity comple- 
mentary to the receptor ensemble (13). Both the receptors 
and the ligands  assemble and function as  homotrimers in 
which the threefold axis of symmetry lies perpendicular to 
the cell membrane. The ligands are clasped on three sides 
by the  CRDs  of the receptors, which adopt an extended 
conformation that projects from the membrane (14).  Each 
ligand appears to bind a single member of the receptor su- 
perfamily, with the exception of TNF and lymphotoxin-o~, 
which bind and signal through both the p55 and p75 TN- 
FRs.  Interestingly, in addition to their roles in cell death, 
Fas ligand  (FasL), TNF, and other ligand family members 
can costimulate resting T  cell proliferation (7). Thus, these 
molecules can exert both positive and negative influences 
over immune responses. 
The importance of Fas was made clear by the identifica- 
tion of  mutations in its gene and the gene for the FasL in Ipr 
and gld mice, respectively (2).  Inbred MILL mice that are 
homozygous for the lpr or gld alleles manifest a syndrome of 
deranged lymphocyte function, including hypergammaglob- 
ulinemia, autoantibody accumulation, arthritis,  vasculitis, and 
glomerulonephritis that is  associated with  massive  expan- 
sions of an unusual population of TCR-cx/I3+CD4-CD8 - 
lymphocytes in the secondary lymphoid tissue (15). The lpr 
allele is a loss-of-function mutation due to the insertion of 
a retrovirus in the Fas locus (2). The gld mutation is a single 
amino acid substitution that inhibits binding of FasL to Fas 
(2).  Interestingly, disease  occurs in animals  that are com- 
pound heterozygotes between gld and another mutant Fas 
allele,  lpt'e, that encodes in the  Fas death domain a single 
amino acid substitution that abolishes its function (2). 
The  marked  abnormalities  in  the  secondary lymphoid 
tissue in Ipr orgld mice without dramatic effects in the bone 
marrow or thymus indicate that the peripheral lymphocyte 
homeostasis is selectively perturbed (2, 15). Specific deficits 
in apoptosis have been documented in both mature B and 
T cells in Ipr andgld mice (16--20). Autoimmune symptoms 
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Figure 1,  Two mechanics ofT lymphocyte death. The "active" death mechanism occurs when IL-2 causes T  cells to become susceptible to apoptosis, 
and further strong TCR cross-linking induces Fas- or TNF-mediated programmed cell death (1). This constitutes a negative feedback mechanism termed 
propriocidal regulation that limits clonal expansion in the face of persistent antigen (1). If no further lymphokine or antigen stimulation is received, T  cell 
may undergo passive death (29).  By mechanisms that are not understood, some T  cells may escape death and persist as "memory" cells (5). 
in lpr and gld mice depend on complex genetic interactions 
in  addition  to  altered lymphocyte homeostasis.  Autoanti- 
bodies and severe end-organ damage occur early in life in 
MRL mice, but may be completely absent in other back- 
grounds, such as C3H (15).  Since MRL mice without Fas 
or  FasL  mutations  can  develop  a  mild  autoimmune  syn- 
drome, it has been suggested that loss of Fas-induced apop- 
tosis exacerbates, but does not cause,  autoimmune disease 
(2).  Though multiple immune cell types could be affected 
by the loss  of Fas, T  cells  are clearly important in causing 
autoimmune disease.  The expression of wild-type Fas in T 
cells alone is sufficient to abrogate disease in lpr mice (21). 
Therefore, the importance of programmed death of mature 
lymphocytes  for  extrathymic  lymphocyte  homeostasis  is 
clearly established by the lpr and gld strains.  Less  clear are 
the  molecular  and  genetic  influences  that  determine  the 
specific autoimmune consequences of abnormal lymphocyte 
homeostasis. 
Significant progress has been made in the past year in de- 
fining  the  relationship  of Fas  to  human  diseases.  Histori- 
cally, the symptoms manifested in the MR.L/lpr mouse have 
been compared with the human autoimmune disease sys- 
temic lupus erythematosus (15). However, lupus patients do 
not experience massive lymph node or spleen enlargement, 
nor do they accumulate TCR-e~/[3+CD4-CD8 -  lympho- 
cytes  as  lpr  mice  do.  Interestingly,  splice  variants  of Fas 
mR.NA forms that  generate potentially soluble  Fas  mole- 
cules that are truncated before the transmembrane portion 
have been described in lupus patients (22).  Such molecules 
are theorized to be soluble decoys that bind to and block 
Fas ligand, but their significance for the pathogenesis of lu- 
pus is uncertain.  The mRNAs encoding soluble Fas forms 
are also detected in normal, healthy individuals (23). 
Recent  attention  has  been  directed  at  diseases  of de- 
ranged lymphocyte homeostasis with onset early in life.  In 
1992,  two  children  were  described  with  autoimmunity, 
marked peripheral lymphoid hyperplasia, and high circulat- 
ing levels ofTCR-0~/[3+CD4-CD8 -  lymphocytes that re- 
sembled the lpr mouse (24).  Cellular and molecular studies 
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of unrelated children with these findings revealed profound 
defects in lymphocyte apoptosis associated with mutations 
in Fas (25,  26). The mutations would be predicted to cause 
abnormalities of the  Fas protein,  including premature ter- 
mination of translation,  deletions of the CILDs that would 
abrogate ligand binding,  and amino  acid substitutions  and 
deletions in the cytoplasmic death domain. Direct structure- 
function analyses showed that the mutant Fas proteins were 
nonfunctional (26). With the molecular pathogenesis in hand, 
the children were grouped into a single nosological entity, 
the autoimmune lymphoproliferative syndrome (ALPS). 
Genetic  analyses of ALPS patients followed at the  Na- 
tional Institutes of Health have been informative. In all cases, 
the  mutations are  inherited,  and  recent  studies  show  that 
certain mutant alleles have been transmitted through at least 
three  generations  (Rosenberg,  F.J.,  M.J.  Lenardo,  and J.J. 
Puck, unpublished observations). One important surprise is 
that mutant Fas alleles in the ALPS patients are usually het- 
erozygous to wild-type  alleles  (26).  The  mutant  Fas  pro- 
teins were found to interfere with the generation of a death 
signal by the normal Fas protein when they were both ex- 
pressed in the same cell (26).  This may be largely due to the 
trimeric structure of Fas. If  the wild-type and mutant alleles 
are equivalently expressed, the probability is (1/2) 3, or 1 in 
8, of a receptor comprising only wild-type subunits. Hence, 
unlike  the recessive lpr allele,  these deleterious human Fas 
mutations are dominant interfering. A second important ob- 
servation is  that  most human  Fas  mutations  are  inherited 
from an individual who has abnormal lymphocyte apopto- 
sis  (when measured in vitro) but no overt clinical signs  of 
ALPS (26).  Thus, like the lymphoproliferative syndrome in 
mice, the ALPS phenotype in humans has variable expres- 
sivity and may depend on other genetic or environmental 
influences. 
To understand  the  full importance of ALPS  or Ipr dis- 
ease,  it is  necessary  to  put  them  into  the  context  of the 
mechanisms that cause T  cell death.  It has been difficult to 
understand  why active antigen-driven  T  cell death  in  the 
midst of an immune response should  take place  (3).  This death process, which affects antigen-specific T  cells but not 
bystander cells, depends on cell-cycle progression caused by 
IL-2 or other T  cell growth lymphokines and is escalated 
with increasing quantities of antigen (27,  28). The conflu- 
ence of high concentrations of IL-2 and antigen powerfully 
upregulates death by Fas-FasL interactions (mainly in CD4 + 
cells) and TNF-TNFR interactions (mainly in CD8 + cells) 
(18).  Why activated, cycling T  cells confronted with their 
cognate antigen will die is therefore a paradox. What ALPS 
reveals is that the active death mechanism is important for 
peripheral T  cell tolerance. Antigen-driven T  cell death is 
essentially a  negative feedback mechanism  that bruits  the 
proliferative response  to  persistent  antigen  (1,  3,  27).  In 
susceptible individuals, the loss of this feedback control can 
lead to T  cell accumulation and significant cross-reactions 
with self-antigens. Also the ALPS and lpr phenotypes have 
a prominent humoral component owing to  autoantibody 
production, implying that the chnical impact ofT cell cross- 
reactions with self may be worsened by altered B  cell ho- 
meostasis caused by Fas deficits (19, 20). Thus, the response 
to antigen must be powerful but also self-bruited. 
By contrast, passive,  lymphokine-withdrawal death may 
dispatch T  lymphocytes that are not retained for memory 
when an antigen has been cleared (29).  Passive  death does 
not require Fas and still occurs in T  cells from lpr mice and 
ALPS patients  (Wang,  R., J.M.  Puck,  and M.J.  Lenardo, 
unpublished results).  Recent work has shown that Ipr mice 
that are overexpressing a bd-2  transgene have dramatically 
increased lymphocyte accumulation compared with what is 
typically found in lpr mice (30). This indicates that both the 
active  and  passive  mechanisms  are  important  for normal 
lymphocyte homeostasis. 
In the present paper,  Simon et al. provide evidence re- 
garding one possible pathological consequence of Fas alter- 
ations in mature hfe (6). A 64-year-old patient who devel- 
oped hypereosinophilic syndrome in middle age was found 
to  have  a  monoclonal  population  of TCR-~/[3+CD4 - 
CD8-  lymphocytes that exhibited altered splice forms of 
Fas  mRNA.  A  37-yr-old HIV-infected individual  mani- 
fested adult-onset hypereosinophilia in association with an 
ohgoclonal expansion ofTCR-o~/[3+CD4-CD8 -  lympho- 
cytes that were devoid of Fas expression. The hypereosino- 
philia was attributed to secretion of a TH2 profile of cyto- 
kines by the double-negative cells that could prolong the 
survival of eosinophils in an in vitro assay. Although a cy- 
tokine cascade could certainly account for the massive  ac- 
cumulation of eosinophils in these patients, it is clear that 
the accumulation of TCR-cx/[3+CD4-CD8 -  lymphocytes 
in  ALPS  patients  or  lpr  mice  does  not  lead  to  hyper- 
eosinophilia.  It would have been interesting to know the 
status  of Fas  in  the  eosinophils  themselves.  Bochner and 
co-workers have shown that  Fas  can mediate apoptosis of 
eosinophils (31),  raising the possibihty of pathological con- 
sequences due to a Fas defect intrinsic to eosinophils. Simi- 
larly, it will be of interest to examine the molecular compo- 
nents of  the active death pathway in other clinical conditions 
in which expansions of hematopoietic cell-types occur in 
adulthood. 
The molecular nature of the Fas defects found in the hy- 
pereosinophihc patients in the Simon et al. study was un- 
clear but apparently differed from that observed in ALPS 
(6, 25, 26). The authors found no germline Fas gene alter- 
ations and concluded that somatic mutations could account 
for the abnormal accumulation of double-negative lympho- 
cytes. Precisely why Fas mRNA was not expressed in one 
patient and why, in another patient, Fas sphcing appeared 
to favor an mRNA lacking the transmembrane domain was 
not defined. As mentioned above, Ruberti and colleagues 
have shown that peripheral blood T cells from normal indi- 
viduals can express a variant of Fas lacking the transmem- 
brane domain (23). Future studies directed at the molecular 
basis of the patient's Fas alterations may illuminate impor- 
tant steps in the regulation of  lymphocyte death. 
Clinically,  the hypereosinophilic syndrome associated with 
apparent somatic Fas alterations contrasts markedly with the 
lymphoid hyperplasia and autoimmunity associated with in- 
herited Fas deficiencies in ALPS (25, 26). These differences 
can best be explained by the fact that the heritable Fas defi- 
ciency will cause defective apoptosis in many immune cell 
types. Thus, a constellation of Fas-defective cells working 
in concert may give a more pleiotropic clinical picture than 
a single lineage of Fas-defective cells.  It will be important 
to study a larger cohort of patients with hypereosinophilia 
to determine how often Fas defects are seen and the range 
of clinical manifestations in such patients. 
The  molecular  association  of abnormal  immune  cell 
death with  clinical diseases  has  provided valuable insights 
into  immune  regulation,  but  the  study  of children  with 
ALPS reminds  us of two bedeviling problems of modem 
human genetics. First,  though certain gene disorders yield 
clear phenotypes, there are often effects due to gene epista- 
sis or the environment that influence the  clinical picture. 
Therefore, "modifier" genes or factors may be critical to 
understanding chnical diseases.  Second, almost any disease 
can be viewed through the prism of genetics, as subtle mu- 
tations in a myriad of cellular proteins can increase or de- 
crease the likelihood of any given pathological process. In 
the case  of Fas, mutations that do not completely destroy 
function may nonetheless influence immune responses and 
autoimmunity.  These  effects  can  only  be  detected  by 
screening patients with immunoregulatory disorders, as was 
done in the study by Simon et al. Despite the complexities, 
the  clear and dramatic phenotypes that have been associ- 
ated  with  molecular abnormalities  of Fas  argue  convinc- 
ingly that a balanced cycle of lymphocyte life and death is 
important for health. 
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